[Federal Register: September 1, 2004 (Volume 69, Number 169)]
[Notices]
[Page 53452-53453]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr01se04-91]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2003N-0455]
Training Program for Regulatory Project Managers; Information
Available to Industry
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) Center for Drug
Evaluation and Research (CDER) is announcing the continuation of the
Regulatory Project Management Site Tours and Regulatory Interaction
Program (the Site Tours Program). This training program was initiated
in 1999, and it is intended to give CDER regulatory project managers an
opportunity to tour pharmaceutical facilities and to exchange
regulatory experiences with their industry counterparts. The Site Tours
Program is intended to enhance review efficiency and quality by
providing CDER staff with a better understanding of the pharmaceutical
industry and its operations. Further, this program is intended to
improve communication and cooperation between CDER staff and industry.
The purpose of this notice is to invite pharmaceutical companies
interested in participating in these programs to contact CDER.
DATES: Pharmaceutical companies may submit proposed agendas to the
agency by November 1, 2004.
FOR FURTHER INFORMATION CONTACT: Beth Duvall-Miller, Office of New
Drugs (HFD-020), Center for Drug Evaluation and Research, Food and Drug
Administration, 5515 Security Lane, rm. 7219, Rockville, MD 20852, 301-
594-3937, FAX: 301-480-8329.
SUPPLEMENTARY INFORMATION:
I. Background
An important part of CDER's commitment to make safe and effective
drugs available to all Americans is optimizing the efficiency and
quality of the drug review process. To support this primary goal, the
center has initiated various training and development programs to
promote high performance
[[Page 53453]]
in its regulatory project management staff. CDER seeks to significantly
enhance review efficiency and review quality by providing the staff
with a better understanding of the pharmaceutical industry and its
operations. To this end, CDER is continuing this training program to
give regulatory project managers the opportunity to tour pharmaceutical
facilities. The goals are to provide the following: (1) First hand
exposure to industry's drug development processes, and (2) a venue for
sharing information about project management procedures (but not drug-
specific information) with industry representatives.
II. Regulatory Project Management Site Tours and Regulatory Interaction
Program
In this program, over a 2- to 3-day period, small groups (five or
less) of regulatory project managers, including a senior level
regulatory project manager, can observe operations of pharmaceutical
manufacturing and/or packaging facilities, pathology/toxicology
laboratories, and regulatory affairs operations. Neither this tour nor
any part of the program is intended as a mechanism to inspect, assess,
judge, or perform a regulatory function, but is meant rather to improve
mutual understanding and to provide an avenue for open dialogue. During
the Site Tours Program, regulatory project managers will also
participate in daily workshops with their industry counterparts,
focusing on selective regulatory issues important to both CDER staff
and industry. The primary objective of the daily workshops is to learn
about the team approach to drug development, including drug discovery,
preclinical evaluation, project tracking mechanisms, and regulatory
submission operations.
The overall benefit to regulatory project managers will be exposure
to project management, team techniques, and processes employed by the
pharmaceutical industry. By participating in this program, the
regulatory project manager will grow professionally by gaining a better
understanding of industry processes and procedures.
III. Site Selection
All travel expenses associated with the site tours will be the
responsibility of CDER, therefore, selection will be based on the
availability of funds and resources for each fiscal year.
Firms interested in offering a site tour or learning more about
this training opportunity should respond within 60 days of this notice
by submitting a proposed agenda to Beth Duvall-Miller (see FOR FURTHER
INFORMATION CONTACT).
Dated: August 24, 2004.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 04-19879 Filed 8-31-04; 8:45 am]
BILLING CODE 4160-01-S